Jeremie Calais

About

Jeremie Calais is an Associate Professor at the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at UCLA. He received his MD degree from the University of Paris-Diderot in 2010 and trained in nuclear medicine and cancer imaging at the Henri Becquerel Cancer Center of the University of Rouen. He was board certified by the French Society of Nuclear Medicine in 2014. His work focuses on improving cancer patient outcomes by translating and applying novel diagnostic and therapeutic approaches, utilizing PET/CT imaging for cancer phenotyping, radiation therapy planning, and therapy response assessment. Dr. Calais leads the clinical research program of Nuclear Medicine and Theranostics at UCLA, which combines radionuclide therapy and imaging. His research is driven by the adoption of PET/CT and the development of Theranostics, a field that integrates tumor-specific targeted radionuclide imaging and therapy. His program involves investigator-initiated and industry-sponsored studies using targeted radionuclide imaging and therapy, with a focus on translatable radiolabeled theranostic pairs for cancer diagnosis and treatment. He collaborates closely with clinical faculty across multiple departments at UCLA and with national and international partners. His team is conducting clinical trials to evaluate the impact of PSMA PET imaging and PSMA radionuclide therapy on prostate cancer care and outcomes, including a joint submission with…

Research topics

• Medicine
• Internal medicine
• Nuclear medicine
• Oncology
• Radiology
• Pathology
• Urology
• Surgery
• Biology
• Engineering

Selected publications

• Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection

  JAMA Oncology · 2021 · 334 citations

  Senior authorCorresponding

  IMPORTANCE: The presence of pelvic nodal metastases at radical prostatectomy is associated with biochemical recurrence after prostatectomy. OBJECTIVE: To assess the accuracy of prostate-specific membrane antigen (PSMA) 68Ga-PSMA-11 positron emission tomographic (PET) imaging for the detection of pelvic nodal metastases compared with histopathology at time of radical prostatectomy and pelvic lymph node dissection. DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated prospective multicen…

  DOI

• Correlation of ⁶⁸Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study

  Journal of Nuclear Medicine · 2021 · 146 citations

  Senior authorCorresponding

  Ga-FAPi-46 PET biodistribution across multiple cancers strongly correlated with FAP tissue expression. These findings support further exploration of FAPi PET as a pancancer imaging biomarker for FAP expression and as a stratification tool for FAP-targeted therapies.

  DOI

• Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study

  Journal of Nuclear Medicine · 2022 · 134 citations

  Lu-PSMA in men with mCRPC. PSA + RECIP may be used as a novel composite endpoint in mCRPC clinical trial design.

  DOI

• Head-to-Head Comparison of⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial

  Journal of Nuclear Medicine · 2021 · 128 citations

  Senior authorCorresponding

  PSMA PET/CT and mpMRI have similar accuracy in the detection and intraprostatic localization of prostate cancer foci. mpMRI performs better in identifying EPE and SVI. For the T-staging evaluation of intermediate to high-risk prostate cancer, mpMRI should still be considered the imaging modality of reference. Whenever available, PSMA PET/MRI or the coregistration or fusion of PSMA PET/CT and mpMRI (PSMA PET/CT + mpMRI) should be used as it improves tumor extent delineation.

  PublisherOA PDFDOI

• SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors

  Journal of Nuclear Medicine · 2023 · 108 citations

  The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. Its 18,000 members are physicians, technologists, and scientists specializing

  PublisherOA PDFDOI

Frequent coauthors

• Johannes Czernin

  245 shared

• Wolfgang P. Fendler

  University of Duisburg-Essen

  207 shared

• Matthias Eiber

  144 shared

• Ken Herrmann

  136 shared

• Matthew B. Rettig

  119 shared

• Thomas A. Hope

  University of California System

  115 shared

• Andrei Gafita

  Johns Hopkins Medicine

  86 shared

• Robert E. Reiter

  85 shared

Labs

• Theranostics Clinical Research ProgramPI

Awards & honors

• Honorary Board Member, SNMMI Correlative Imaging Council (CI…
• Committee Member, Prostate Theranostics and Imaging Centre o…

Similar researchers at University of California, Los Angeles

• Timothy Cloughesyh-173
• Daniel H. Silvermanh-85